Respiratory

Also known as coal workers’ pneumoconiosis, black lung disease (or miner’s lung) is typically the result of inhaling coal dust for many years that causes scarring in the lungs and makes breathing increasingly difficult. The prevalence of black lung has been on the rise in the US.

Early intervention for idiopathic pulmonary fibrosis (IPF) is crucial due to the high mortality rate, with emerging therapies like nerandomilast showing potential to reduce health care costs by preventing disease progression.

The identification of unique pulmonary fibrosis endotypes is an important step in the development of precision medicine approaches for the incurable condition.

Looking to the future of bronchiectasis treatment, Panagis Galiatsatos, MD, MHS, outlines challenges in the current therapeutic landscape and discusses ways to potentially improve care.

A pulmonary specialist shares his approach to treating patients with bronchiectasis, highlighting gaps in knowledge that impact management practices.

Martin Kolb, MD, PhD, discusses the challenges of treating idiopathic pulmonary fibrosis (IPF) and highlights the potential benefits of a new PDE4B inhibitor, nerandomilast.

Panagis Galiatsatos, MD, MHS, provides clinical insights on resources and factors that inform the treatment of patients with bronchiectasis.

An expert on bronchiectasis describes the extensive impact of exacerbations on patients’ lives and the health care system.

A pulmonary and critical care medicine physician discusses how bronchiectasis compares with other chronic respiratory disorders, highlighting the differing signs and symptoms.

Panagis Galiatsatos, MD, MHS, provides an overview of clinical presentations that prompt consideration of bronchiectasis in the differential diagnosis.

While both drugs slowed down lung function decline in idiopathic pulmonary fibrosis (IPF), they were also linked to more deaths and increased incidence of acute exacerbation of IPF in real-world settings.

Patients with fibrosing interstitial lung disease (ILD) who began supplemental oxygen therapy had triple the per patient per month ILD-related health care costs compared with those who did not.

Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention.

The annual number of publications on macrophages and pulmonary fibrosis jumped during 2017 and 2020, with signs pointing to more focus on research in these fields.

Research highlighted the pivotal role of P2RX7 in driving inflammatory and fibrotic processes in idiopathic pulmonary fibrosis (IPF).

Underserved communities, already facing higher asthma prevalence due to social determinants of health, are disproportionately affected by the impact climate change is having on asthma exacerbations. Potential solutions include education for patients and health care providers, climate litigation to establish environmental rights, and policy changes to curb climate change.

Asthma is worsening under the effects of climate change, such as air pollution and pollen production, especially for underserved populations.

However, registry data also showed no significant difference in transplant-free survival and time to pulmonary function decline between patients receiving antifibrotics vs placebo.

More than 100 therapies for idiopathic pulmonary fibrosis are being developed across the globe.

The ENV-101 phase 2a trial for idiopathic pulmonary fibrosis (IPF) focused on assessing safety, lung function, and fibrosis, with plans for further trials, combination therapies, and strategies to manage adverse effects.

John Hood, PhD, cofounder and CEO of Endeavor BioMedicines, explains the potential advantages of ENV-101 during a time with very few treatments for idiopathic pulmonary fibrosis (IPF).

The proof-of-concept study also identified key metabolites that correlated with pulmonary fibrosis diagnosis and disease progression.

Idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and other interstitial lung diseases are more significantly associated with poor 30-day outcomes from COVID-19 compared with asthma.

Our top coverage from the CHEST Annual Meeting 2023 explored various topics, including strategies to prevent air pollutant exposure and keys to achieving equity in lung cancer screenings.

This year’s most-read respiratory articles explored a variety of topics, including the effects of marijuana and vaping on the lungs.